Search Results

Aspen Surgical Products, Inc. (“Aspen”), a portfolio company of Audax Private Equity (“Audax”) and a leader in disposable surgical products, announced the acquisition of Symmetry Surgical (“Symmetry”) from RoundTable Healthcare Partners. Symmetry represents Aspen’s 15th acquisition in total and sixth since Audax’ initial investment in Aspen in 2019.

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed greater improvements after 96 weeks of treatment in an advanced disease population.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced publication of results in Clinical Gastroenterology and Hepatology from an expansion cohort (Cohort D, N=31) of the Phase 2b SYMMETRY study.